Case of Twins with Rare Stem Cell Disorder Wins Best Overall Abstract at Congress on MPNs
At the 14th International Congress on Myeloproliferative Neoplasms, research into the case of dizygotic twins with essential thrombocythemia won the Best overall Abstract Award for concluding how their rare stem cell disorder was passed between both twins.
Latest Data on JAK Inhibitors Help Optimize Treatment of Myelofibrosis
At the 14th International Congress on Myeloproliferative Neoplasms, Srdan Verstovsek, MD, PhD, reviewed the research supporting the optimal use of JAK inhibitors in patients with myelofibrosis.
Investigational Agents for JAKi-Refractory Myelofibrosis
Following JAK inhibitor therapy, multiple agents are showing the ability to reduce symptoms and spleen volume while improving survival in patient with myelofibrosis.
MPN Landscape Shifts from JAKi Monotherapy to Combining Novel Agents
During a presentation at the 14th Annual International Congress on Myeloproliferative Neoplasms, Naveen Pemmaraju, MD, discussed the current agents being examined for MPNs.
2 Commerce Drive Cranbury, NJ 08512